Press Releases
Mazankowski Alberta Heart Institute Starts Study Comparing Ventripoint Heart Analysis to Contrast Enhanced 2D EchocardiographyToronto, Ontario, July 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that the Mazankowski Alberta Heart Institute in Edmonton, Alberta has begun a study to evaluate the ability of the Ventripoint VMS+ heart analysis system to analyze poor quality images, where contrast enhanced 2D echocardiography would normally be performed to get better images. Read more...
MD Anderson Cancer Center is the First Hospital in USA to Order the VMS+ Complete Heart Analysis SystemToronto, Ontario, June 6, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that MD Anderson Cancer Center in Houston, Texas has ordered the VMS+ complete heart analysis system for use in clinical evaluations of cancer patients. Read more...
Ventripoint adds Experienced Cardiac Sonographer to the Installation and Training TeamToronto, Ontario, May 23, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce the appointment of Jim Graba, BSc, RDCS, FASE as Application Specialist and Chief Trainer. Jim will take the clinical lead in the deployment and training of customers. In addition, he will provide product strategy and direction for the development team. Read more...
Ventripoint Receives Market Clearance from US-FDA for Complete Heart Analysis System using 2D UltrasoundToronto, Ontario – May 15, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) announces that it has received market clearance from the US Food and Drug Administration (“FDA”) to sell its VMS+™ machine with the 4-chamber heart analysis system in the United States. Read more....
Ventripoint Attends the Canadian Society of Echocardiography Conference in TorontoToronto, Ontario, April 23, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it exhibited at the 20th annual Canadian Society of Echocardiography conference which was recently held in Toronto. Read more...
Ventripoint to Issue Shares for Service to CEO and ConsultantsToronto, Canada – March 29, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that it has agreed to issue to Dr. George Adams, CEO of Ventripoint, 375,000 common shares of the Company in payment of outstanding back pay of $120,000, subject to the approval of the TSX Venture Exchange (TSXV). Read more...
Ventripoint and Ryerson University Have Been Approved for Government Funding to Advance Artificial Intelligence in Medical ImagingToronto, Ontario, March 26, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce its participation in a Natural Sciences and Engineering Research Council (NSERC) Engage grant for the development of automatic detection of all four chambers of the heart in echocardiographic views using artificial intelligence (AI), which will reduce time spent on analysis and training costs, and improve accuracy and comparability. Read more...
Ventripoint Appoints Dr. Samuel Schwartz Chair of Business Advisory CommitteeToronto, Ontario, March 14, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has created a Business Advisory Committee (BAC) and has appointed Dr. Samuel Schwartz as the inaugural Chairman. The BAC will provide senior management and the Board of Directors with strategic advice on matters including, but not limited to, financing alternatives and opportunities, market opportunities, human resource insights, and new technology perspectives, in addition to carrying out special assignments. Read more...
Ventripoint Named to 2018 TSX Venture 50 Group of Top Performing Companies
Toronto, Canada – February 22, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that it has been named to the 2018 TSX Venture 50, a ranking of the top performers on the TSX Venture Exchange over the last year.
Read more... First Ventripoint Whole Heart System Operational at University of Alberta Mazankowski Heart InstituteToronto, Canada – February 21, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce the installation of the VMS+ whole heart analysis system at the University of Alberta Mazankowski Alberta Heart Institute under the supervision of Dr. Jonathan Windram, Staff Cardiologist, Northern Alberta Adult Congenital Heart Program and Associate Clinical Professor of Medicine, Division of Cardiology, Department of Medicine, University of Alberta Mazankowski Alberta Heart Institute. Read more...
Ventripoint Adds Hospital Networking Expert to Implementation TeamToronto, Ontario, February 7, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that Dr. Andriy Shmatukha has joined the Ventripoint team as software developer to advance the Ventripoint products and technology. Read more...
Ventripoint Applies to US FDA for Market Clearance for the VMS+ Whole-Heart Analysis SystemToronto, Ontario, January 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has submitted a traditional 510(k) application to the FDA’s Center for Devices and Radiological Health (CDRH) to request clearance for sale of the VMS+ whole-heart analysis system. Read more...
Ventripoint Appoints Head of Sales for North AmericaToronto, Canada – January 10, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce the appointment of David McPhedran as Director of Sales for North America, effective immediately. Read more...
Ventripoint Receives CE Mark for VMS+ Whole Heart Analysis SystemToronto, Ontario, January 8, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has received the European CE Mark for the VMS+ Whole Heart Analysis System, which allows the Company to begin selling the VMS+ throughout the European Union. Read more...
Ventripoint Applies for CE Mark for VMS+ Device and Complete Heart Analysis SystemToronto, Ontario, December 20, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has applied to its Notified Body in Europe to add the new product, VMS+, to its CE Mark and to its certified quality system. Read more...
Ventripoint Provides Corporate UpdateToronto, Ontario, December 19, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has hired a Manager of Regulatory Affairs and Quality Assurance, promoted to President the VP, Development and Operations, completed the ISO60601 safety testing for the VMS+ device and moved its Development and Manufacturing Centre, as well as its Corporate Offices. Read more...
Ventripoint Exhibits at Major Heart Imaging Conference in EuropeToronto, Ontario, December 6, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it is exhibiting at the EuroEcho- Imaging 2017 Conference in Lisbon, Portugal, December 6 – 8, 2017. The Conference is the world’s largest cardiovascular imaging congress. Read more...
Ventripoint Invents a New Way to Track Ultrasound Probes That Will Speed Up ExamsToronto, Ontario, November 27, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has filed a patent to claim the invention of a small, low-cost device that attaches or is encased in any hand-held probe or ultrasound transducer. The invention also includes a method to use the device to track the probe’s position in 3-dimensional space, as well as its orientation. Read more...
Ventripoint Establishes Partnership with the SEED Group from Dubai to Begin Deploying VMS-PLUS Heart Analysis Systems in the Middle EastToronto, Ontario, November 15, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has signed a memorandum of understanding establishing a partnership with the SEED Group, a group of diversified companies owned and chaired by The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum of Dubai, United Arab Emirates. Read more...
Ventripoint Provides Corporate UpdateToronto, Ontario, September 20, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to provide a corporate update on its marketing and development plans. Read more...
Ventripoint Reports on Use of VMS Heart Analysis System to Reliably Measure Remodelling of the Right VentricleToronto, Ontario, August 21, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) announces that the cardiology group at Royal Free Hospital in London, UK has published a study entitled “Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension” in Echocardiography, volume 34, pages 817–824. "Read more.."
Ventripoint Announces Results of Annual Shareholders’ Meeting and Grant of Options and DSUs Toronto, Ontario, August 16, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that at its Annual General Meeting on August 14, 2017 the shareholders re-elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz, Dr. Don Segal and Mr. David Willis as Directors of the Corporation. "Read more..."
A Third Highly Successful Ultrasound Executive Joins VentripointToronto, Canada – July 20, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is announcing the appointment of Desmond Hirson as Vice-President, Development and Operations. "Read more..."
Highly Successful Global Industry (Ultrasound) Sales & Marketing Executives Hired by VentripointToronto, Canada – June 21, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is announcing the appointment of Brian Leck as Vice-President of Direct Worldwide Sales and Mehran Mehrtash as Vice President, Worldwide Distributor Sales, both effective July 1, 2017. "Read more..."
Ventripoint Provides Corporate Update on Sales InitiativesToronto, Canada – June 8, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to provide a corporate update on its business activities. "Read more..."
Ventripoint Diagnostics Ltd is Featured on CEO Clips Airing on BNNToronto, Ontario - March 30, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) is please to announce the Corporation is being featured this week on CEO Clips airing on BNN. CEO Clips, profiles some of the most innovative publicly-traded companies in North America and will feature a 15 to 30 second clip about Ventripoint on BNN beginning today. The clip can also be viewed online via this link: http://www.b-tv.com/ventripoint-diagnostics-commercial/
Ventripoint Announces Conversion of all Outstanding
|
For further information please contact:
Dr. George Adams, CEO
Phone: (519) 803-6937
Email: gadams@ventripoint.com
|
